Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04148989
Other study ID # 1051053
Secondary ID K23GM129661
Status Completed
Phase N/A
First received
Last updated
Start date November 13, 2018
Est. completion date December 28, 2023

Study information

Verified date February 2024
Source Intermountain Health Care, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Sepsis is a life-threatening complication of infection that can be difficult to recognize and treat promptly. Timely administration of antibiotics for emergency department (ED) patients with sepsis is challenging. The goal of this study is to determine the potential effectiveness and unintended consequences of reorganizing ED care for patients with suspected sepsis.


Recruitment information / eligibility

Status Completed
Enrollment 180402
Est. completion date December 28, 2023
Est. primary completion date January 23, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria (overall): 1. Adult (age =18 years) 2. ED patient at Intermountain Medical Center, Utah Valley Hospital, Dixie Regional Medical Center 3. Arrival to study emergency department (ED) during study period of 11/13/2018 to 2/12/2021. Exclusion criteria (overall): (1) Trauma patient

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Code Sepsis protocol (full implementation)
Implementation of a coordinated, structured, multidisciplinary team-based protocol for initial evaluation and treatment of ED patients with suspected sepsis.

Locations

Country Name City State
United States Intermountain Medical Center Murray Utah
United States Utah Valley Hospital Provo Utah
United States Dixie Regional Medical Center Saint George Utah

Sponsors (2)

Lead Sponsor Collaborator
Intermountain Health Care, Inc. National Institute of General Medical Sciences (NIGMS)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Antibiotic Utilization' Fraction of all ED patients receiving antibiotics within 24 hours of ED arrival Up to 24 hours from ED arrival (an average of 6 hours)
Other Adverse Effects of Antibiotics (Sepsis Patients) Measured as the fraction of sepsis patients with a discharge diagnosis code consistent with anaphylaxis or with an adverse reaction to antibiotics From the time of ED arrival to hospital discharge (up to 1 year, average 14 days)
Other Adverse Effect of Antibiotics (All ED Patients) Measured as the fraction of all ED patients with a discharge diagnosis code consistent with anaphylaxis or with an adverse reaction to antibiotics From the time of ED arrival to hospital discharge (up to 1 year, average 14 days)
Other New Onset Clostridium Difficile Colitis Incidence (Sepsis Patients) Incidence of positive stool test for Clostridium difficile colitis between 72 hours and 90 days after ED arrival among ED sepsis patients and (2) all ED patients. Beginning 72 hours after ED arrival to 90 days after ED arrival
Other New Onset Clostridium Difficile Colitis Incidence (All ED Patients) Incidence of positive stool test for Clostridium difficile colitis between 72 hours and 90 days after ED arrival among all ED patients. Beginning 72 hours after ED arrival to 90 days after ED arrival.
Other Antibiotic Overtreatment Rate Fraction of ED patients with a primary hospital discharge diagnosis of congestive heart failure or venous thromboembolism and no discharge diagnosis consistent with infection who received antibiotics in the ED Up to 24 hours from ED arrival (an average of 6 hours)
Other Antibiotic Spectrum (Sepsis Patients) Total antibiotic spectrum score for all unique antibiotics administered in first 24 hours using antibiotic spectrum scoring system developed by Stenehjem et al. (Clin Infect Dis 2016;63:1273-1280). Individual antibiotics have spectrum scores of 1 to 5, with the total score resulting from summation of the spectrum scores for each unique antibiotic administered during the first 24 hours. Minimum total 24-hour score is therefore 1 (administration of a single, minimum-spectrum antibiotic), with no maximum score. Higher values represent treatment with antibiotics with a broader spectrum. Up to 24 hours from ED arrival (an average of 6 hours)
Other Antibiotic Spectrum (All ED Patients) Total antibiotic spectrum score for all unique antibiotics administered in first 24 hours using antibiotic spectrum scoring system developed by Stenehjem et al. (Clin Infect Dis 2016;63:1273-1280). Individual antibiotics have spectrum scores of 1 to 5, with the total score resulting from summation of the spectrum scores for each unique antibiotic administered during the first 24 hours. Minimum total 24-hour score is therefore 1 (administration of a single, minimum-spectrum antibiotic), with no maximum score. Higher values represent treatment with antibiotics with a broader spectrum. Up to 24 hours from ED arrival (an average of 6 hours)
Primary Door-to-antibiotic Time Time from sepsis patients' emergency department arrival to intravenous (or equivalent) antibiotic initiation Up to 24 hours from ED arrival (an average of 3 hours)
Secondary All-cause 30-day Mortality Sepsis patient death on or before the 30th day after ED arrival 30 days after ED arrival
Secondary All-cause 1-year Mortality Sepsis patient death on or before the 365th day after ED arrival 1 year after ED arrival
Secondary All-cause In-hospital Mortality Sepsis patient death prior to hospital discharge From the time of admission to hospital discharge (up to 1 year, average 14 days)
Secondary Hospital Charges Amount charged to sepsis patient for their medical care during index ED visit and associated hospitalization From the time of admission to hospital discharge (up to 1 year, average 14 days)
Secondary Hospital Length of Stay Length of time from sepsis patients' ED arrival until hospital discharge From the time of admission to hospital discharge (up to 1 year, average 14 days)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3